[Form 4] Royalty Pharma plc Insider Trading Activity
Pablo G. Legorreta, CEO and Chairman of Royalty Pharma plc, filed a Form 4 reporting an exempt acquisition on 08/06/2025 of 21,901 Class A Ordinary Shares at $0 in connection with settlement of Equity Performance Awards pursuant to Rule 16b-3. The transaction is recorded as an exempt award settlement and increases the reporting persons direct holdings.
The filing itemizes extensive indirect beneficial ownership through entities, trusts and family members with specific share counts such as Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590 and Legorreta 2023 SR Trust: 600,000, among others.
The form also discloses LP interests in RPI US Partners 2019, LP that are exchangeable under the Amended and Restated Exchange Agreement into Class A Ordinary Shares for no additional value; entries include a reported change dated 08/08/2025 listing 60,000 LP interests (noted as representing 600,000 Class A Ordinary Shares) and larger RPI US LP interest amounts shown for related entities.
Pablo G. Legorreta, CEO e Presidente di Royalty Pharma plc, ha depositato un Modulo 4 segnalando un'acquisizione esente in data 08/06/2025 di 21,901 Class A Ordinary Shares al prezzo di $0 in relazione alla liquidazione di Equity Performance Awards ai sensi della Rule 16b-3. La transazione è registrata come liquidazione di premio esente e aumenta le partecipazioni dirette della persona segnalante.
La dichiarazione elenca una consistente titolarità beneficiaria indiretta attraverso entità, trust e membri della famiglia, con conteggi specifici quali Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590 e Legorreta 2023 SR Trust: 600,000, tra gli altri.
Il modulo segnala inoltre quote LP in RPI US Partners 2019, LP convertibili, ai sensi dell'Amended and Restated Exchange Agreement, in azioni ordinarie di classe A senza ulteriore corrispettivo; tra le voci figura una modifica riportata in data 08/08/2025 che indica 60,000 interessi LP (specificati come rappresentanti 600,000 Class A Ordinary Shares) e importi maggiori di interessi RPI US LP mostrati per entità correlate.
Pablo G. Legorreta, CEO y Presidente de Royalty Pharma plc, presentó un Formulario 4 informando una adquisición exenta el 08/06/2025 de 21,901 Class A Ordinary Shares por $0 en relación con la liquidación de Equity Performance Awards conforme a la Regla 16b-3. La operación se registra como una liquidación de premio exenta y aumenta las participaciones directas del declarante.
La presentación detalla una amplia propiedad beneficiaria indirecta a través de entidades, fideicomisos y miembros de la familia, con conteos específicos como Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590 y Legorreta 2023 SR Trust: 600,000, entre otros.
El formulario también revela intereses LP en RPI US Partners 2019, LP que son canjeables, bajo el Amended and Restated Exchange Agreement, por acciones ordinarias de Clase A sin valor adicional; las entradas incluyen un cambio reportado con fecha 08/08/2025 que enumera 60,000 intereses LP (indicados como representativos de 600,000 Class A Ordinary Shares) y montos mayores de intereses RPI US LP mostrados para entidades relacionadas.
Pablo G. Legorreta, Royalty Pharma plc의 CEO 겸 이사회 의장은 08/06/2025자로 예외적 취득을 보고하는 Form 4를 제출했습니다. 해당 보고서는 Rule 16b-3에 따라 Equity Performance Awards 정산과 관련해 21,901 Class A Ordinary Shares를 $0에 취득한 것으로 기재되어 있습니다. 이 거래는 예외적 상환(예외적 보상 정산)으로 기록되며 신고인의 직접 보유 지분을 증가시킵니다.
신고서에는 법인, 신탁 및 가족 구성원을 통한 광범위한 간접 수혜권 보유가 항목별로 기재되어 있으며, 예를 들어 Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590, Legorreta 2023 SR Trust: 600,000 등이 포함됩니다.
또한 양식에는 RPI US Partners 2019, LP에 대한 LP 지분이 Amended and Restated Exchange Agreement에 따라 추가 대가 없이 Class A 보통주로 교환 가능하다고 공개되어 있습니다. 항목 중에는 08/08/2025자로 보고된 변경 사항이 있어 60,000 LP 지분(이는 600,000 Class A Ordinary Shares에 해당한다고 명시)과 관련 법인에 대해 더 많은 RPI US LP 지분 수량이 표기되어 있습니다.
Pablo G. Legorreta, PDG et président de Royalty Pharma plc, a déposé un Formulaire 4 déclarant une acquisition exonérée le 08/06/2025 de 21,901 Class A Ordinary Shares pour $0 dans le cadre du règlement d'Equity Performance Awards conformément à la règle 16b-3. La transaction est enregistrée comme un règlement de prime exonéré et augmente les participations directes de la personne déclarante.
Le dépôt détaille une importante propriété bénéficiaire indirecte via des entités, des trusts et des membres de la famille, avec des nombres précis tels que Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590 et Legorreta 2023 SR Trust: 600,000, entre autres.
Le formulaire révèle également des intérêts LP dans RPI US Partners 2019, LP échangeables en actions ordinaires de classe A en vertu de l'Amended and Restated Exchange Agreement sans contrepartie supplémentaire ; les rubriques incluent une modification signalée en date du 08/08/2025 indiquant 60,000 intérêts LP (mentionnés comme représentant 600,000 Class A Ordinary Shares) ainsi que des montants plus importants d'intérêts RPI US LP pour des entités liées.
Pablo G. Legorreta, CEO und Vorsitzender von Royalty Pharma plc, hat ein Formular 4 eingereicht, das eine befreite Anschaffung am 08/06/2025 von 21,901 Class A Ordinary Shares zu $0 im Zusammenhang mit der Abwicklung von Equity Performance Awards gemäß Rule 16b-3 meldet. Die Transaktion ist als befreite Gewährungsabwicklung erfasst und erhöht die direkten Bestände der meldenden Person.
Die Einreichung führt umfangreiches indirektes wirtschaftliches Eigentum über Gesellschaften, Trusts und Familienmitglieder auf, mit konkreten Stückzahlen wie Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590 und Legorreta 2023 SR Trust: 600,000, unter anderen.
Das Formular legt außerdem LP-Anteile an RPI US Partners 2019, LP offen, die gemäß dem Amended and Restated Exchange Agreement ohne zusätzlichen Gegenwert in Class A Ordinary Shares umtauschbar sind; Einträge umfassen eine am 08/08/2025 gemeldete Änderung, die 60,000 LP-Anteile auflistet (angegeben als repräsentierend für 600,000 Class A Ordinary Shares) sowie größere RPI US LP-Anteilsmengen für verbundene Einheiten.
- None.
- None.
Insights
TL;DR: CEO received 21,901 shares via award settlement; filing shows substantial indirect and exchangeable holdings that affect insider ownership structure.
The Form 4 documents a routine, exempt equity award settlement for Pablo Legorreta, adding 21,901 Class A shares at no cash cost to the reporting person. More materially, the filing catalogs numerous indirect holdings across trusts and entities and significant limited partnership interests in RPI US Partners 2019 that are exchangeable into Class A shares under the stated exchange agreement. These exchangeable interests are explicitly described as convertible for no additional value, which is a structural feature investors should note when assessing potential future share issuance and insider alignment.
TL;DR: The filing shows executive compensation settled in equity and concentrated insider ownership with convertible partnership interests disclosed.
The disclosure confirms an equity-based compensation settlement for the CEO and a complex ownership map including direct, indirect and family/trust holdings. It also outlines contractual exchange rights tied to RPI US Partners 2019 interests and the Amended and Restated Exchange Agreement, with the explicit statement that exchanges can be made for no additional value. From a governance perspective, the combination of award settlements and broad, exchangeable interests can influence voting control and capitalization over time; the form provides clear counts and the contractual terms referenced by the filer.
Pablo G. Legorreta, CEO e Presidente di Royalty Pharma plc, ha depositato un Modulo 4 segnalando un'acquisizione esente in data 08/06/2025 di 21,901 Class A Ordinary Shares al prezzo di $0 in relazione alla liquidazione di Equity Performance Awards ai sensi della Rule 16b-3. La transazione è registrata come liquidazione di premio esente e aumenta le partecipazioni dirette della persona segnalante.
La dichiarazione elenca una consistente titolarità beneficiaria indiretta attraverso entità, trust e membri della famiglia, con conteggi specifici quali Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590 e Legorreta 2023 SR Trust: 600,000, tra gli altri.
Il modulo segnala inoltre quote LP in RPI US Partners 2019, LP convertibili, ai sensi dell'Amended and Restated Exchange Agreement, in azioni ordinarie di classe A senza ulteriore corrispettivo; tra le voci figura una modifica riportata in data 08/08/2025 che indica 60,000 interessi LP (specificati come rappresentanti 600,000 Class A Ordinary Shares) e importi maggiori di interessi RPI US LP mostrati per entità correlate.
Pablo G. Legorreta, CEO y Presidente de Royalty Pharma plc, presentó un Formulario 4 informando una adquisición exenta el 08/06/2025 de 21,901 Class A Ordinary Shares por $0 en relación con la liquidación de Equity Performance Awards conforme a la Regla 16b-3. La operación se registra como una liquidación de premio exenta y aumenta las participaciones directas del declarante.
La presentación detalla una amplia propiedad beneficiaria indirecta a través de entidades, fideicomisos y miembros de la familia, con conteos específicos como Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590 y Legorreta 2023 SR Trust: 600,000, entre otros.
El formulario también revela intereses LP en RPI US Partners 2019, LP que son canjeables, bajo el Amended and Restated Exchange Agreement, por acciones ordinarias de Clase A sin valor adicional; las entradas incluyen un cambio reportado con fecha 08/08/2025 que enumera 60,000 intereses LP (indicados como representativos de 600,000 Class A Ordinary Shares) y montos mayores de intereses RPI US LP mostrados para entidades relacionadas.
Pablo G. Legorreta, Royalty Pharma plc의 CEO 겸 이사회 의장은 08/06/2025자로 예외적 취득을 보고하는 Form 4를 제출했습니다. 해당 보고서는 Rule 16b-3에 따라 Equity Performance Awards 정산과 관련해 21,901 Class A Ordinary Shares를 $0에 취득한 것으로 기재되어 있습니다. 이 거래는 예외적 상환(예외적 보상 정산)으로 기록되며 신고인의 직접 보유 지분을 증가시킵니다.
신고서에는 법인, 신탁 및 가족 구성원을 통한 광범위한 간접 수혜권 보유가 항목별로 기재되어 있으며, 예를 들어 Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590, Legorreta 2023 SR Trust: 600,000 등이 포함됩니다.
또한 양식에는 RPI US Partners 2019, LP에 대한 LP 지분이 Amended and Restated Exchange Agreement에 따라 추가 대가 없이 Class A 보통주로 교환 가능하다고 공개되어 있습니다. 항목 중에는 08/08/2025자로 보고된 변경 사항이 있어 60,000 LP 지분(이는 600,000 Class A Ordinary Shares에 해당한다고 명시)과 관련 법인에 대해 더 많은 RPI US LP 지분 수량이 표기되어 있습니다.
Pablo G. Legorreta, PDG et président de Royalty Pharma plc, a déposé un Formulaire 4 déclarant une acquisition exonérée le 08/06/2025 de 21,901 Class A Ordinary Shares pour $0 dans le cadre du règlement d'Equity Performance Awards conformément à la règle 16b-3. La transaction est enregistrée comme un règlement de prime exonéré et augmente les participations directes de la personne déclarante.
Le dépôt détaille une importante propriété bénéficiaire indirecte via des entités, des trusts et des membres de la famille, avec des nombres précis tels que Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590 et Legorreta 2023 SR Trust: 600,000, entre autres.
Le formulaire révèle également des intérêts LP dans RPI US Partners 2019, LP échangeables en actions ordinaires de classe A en vertu de l'Amended and Restated Exchange Agreement sans contrepartie supplémentaire ; les rubriques incluent une modification signalée en date du 08/08/2025 indiquant 60,000 intérêts LP (mentionnés comme représentant 600,000 Class A Ordinary Shares) ainsi que des montants plus importants d'intérêts RPI US LP pour des entités liées.
Pablo G. Legorreta, CEO und Vorsitzender von Royalty Pharma plc, hat ein Formular 4 eingereicht, das eine befreite Anschaffung am 08/06/2025 von 21,901 Class A Ordinary Shares zu $0 im Zusammenhang mit der Abwicklung von Equity Performance Awards gemäß Rule 16b-3 meldet. Die Transaktion ist als befreite Gewährungsabwicklung erfasst und erhöht die direkten Bestände der meldenden Person.
Die Einreichung führt umfangreiches indirektes wirtschaftliches Eigentum über Gesellschaften, Trusts und Familienmitglieder auf, mit konkreten Stückzahlen wie Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590 und Legorreta 2023 SR Trust: 600,000, unter anderen.
Das Formular legt außerdem LP-Anteile an RPI US Partners 2019, LP offen, die gemäß dem Amended and Restated Exchange Agreement ohne zusätzlichen Gegenwert in Class A Ordinary Shares umtauschbar sind; Einträge umfassen eine am 08/08/2025 gemeldete Änderung, die 60,000 LP-Anteile auflistet (angegeben als repräsentierend für 600,000 Class A Ordinary Shares) sowie größere RPI US LP-Anteilsmengen für verbundene Einheiten.
FAQ
Who filed the Form 4 for Royalty Pharma (RPRX)?
What transaction is reported on the Form 4 dated 08/06/2025 for RPRX?
Did the filer pay cash for the shares reported on the Form 4?
What indirect holdings are disclosed by the reporting person?
What are the RPI US Partners 2019 LP interests disclosed?
Are exchanges for RPI US LP interests described as requiring payment?
